Re: RVX AGM Q&A, post AGM-huddle, impressions

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Cabel

Rank: Treasurer [?]

Points: 1655 [?]

Votes: 16 Score: 2.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: RVX AGM Q&A, post AGM-huddle, impressions

posted on Sep 20, 2018 09:48AM

Thanks for your post!

The company presentation I posted also included pipeline values (market cap) of Phase III companies in this category. They ranged from $8B to 13B, before they all crashed on failed their Phase III results. That's for just high-risk CVD.

More recently Biogen's market cap increased $15B US over a couple of days on a report that they showed results of potenitally slowing AD progression by 30%.

- Impressive!!

...Not halting AD. And far from reversing the effects and damage of AD. (biogen news) Imagine the value the market would assign to a drug that demonstrates plaque reversal and cognitive improvment vs just slowed-down cognitive degradation? That's just for Alzheimer's.

- Yes I can imagine that,... it would be incredible for the patients and the shareholders!

I hesitate to post my math on what our market cap should grow to because it seems at first gance, to the untrained eye, to be ludicrous against the current SP. I take hints from how markets in the recent past have reacted to news and valued companies that have been in the home stretch to having a drug with a decent RRR expectation.